Lupin gets USFDA’s tentative nod for Apalutamide Tablets

13 Oct 2023 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60 mg, to market a generic equivalent of Erleada Tablets, 60 mg of Janssen Biotech, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.  Apalutamide Tablets, 60 mg, (RLD Erleada) had estimated annual sales of $1,185.5 million in the U.S. (IQVIA MAT July 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2107.40 4.10 (0.19%)
02-Jan-2026 14:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1727.20
Dr. Reddys Lab 1252.85
Cipla 1509.85
Zydus Lifesciences 916.30
Lupin 2107.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×